About Argenx N.V. (adapted from Argenx N.V. prospectus):
They are a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their ordinary shares are listed on Euronext Brussels under the symbol 'ARGX'. On May 5, 2017, the last reported sale price of their ordinary shares on Euronext Brussels was 16.59 euros per share, equivalent to a price of $18.18 per share, based on an exchange rate of $1.0961 to 1.00 euro.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.